Last reviewed · How we verify
Placebo plus best supportive care — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo plus best supportive care (Placebo plus best supportive care) — Shanghai Miracogen Inc.. Placebo plus best supportive care provides no active pharmacological intervention, serving as a control arm to evaluate the efficacy of investigational treatments.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo plus best supportive care TARGET | Placebo plus best supportive care | Shanghai Miracogen Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo plus best supportive care CI watch — RSS
- Placebo plus best supportive care CI watch — Atom
- Placebo plus best supportive care CI watch — JSON
- Placebo plus best supportive care alone — RSS
Cite this brief
Drug Landscape (2026). Placebo plus best supportive care — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-plus-best-supportive-care. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab